Biofrontera acquires U.S. rights to Ameluz/RhodoLED from Biofrontera AG; raises $11M via Series C preferred

Biofrontera Inc.

Acquired all U.S. rights to Ameluz and RhodoLED from Biofrontera AG; will pay royalty of 12% or 15% based on $65M revenue threshold.
Biofrontera AG receives 3,109 Series D Convertible Preferred shares (10% post-money equity stake) as part of consideration.
Private placement of up to 11,000 Series C Preferred shares at $1,000 each for gross proceeds of up to $11.0M to fund the deal.
Initial closing of $8.5M expected July 1, 2025; subsequent closing of $2.5M expected by September 30, 2025.
Conversion and voting rights of both preferred series are subject to stockholder approval under Nasdaq rules.

item 1.01item 3.02item 3.03item 5.03item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.